Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer
Approved for marketing · NCT05172700
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Lymphocytic, Small, Lymphoma, Mantle-Cell, Waldenstrom Macroglobulinemia, Ritcher's Transformation, Syndrome
At a glance
- Research payments reported, 2025
- $2,772
- U.S. investigators named
- 8
- Sites paid
- 1
About the trial
- Sponsor
- Loxo Oncology, Inc.
- Tested
- Pirtobrutinib (drug)
- Results posted
- Not yet
This is an expanded access program for eligible participants with a previously treated B-cell cancer who are ineligible for an ongoing pirtobrutinib clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
From ClinicalTrials.gov, last updated 2024-12-18. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $2,772 in research payments for this study in 2025 (8 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Zachary A. Sporn, MD Student in an Organized Health Care Education/Training Program · Boston, MA
- Alexandra Hall, MD Internal Medicine · Minneapolis, MN
- Trent L. Wei, MD Interventional Cardiology · Greensboro, NC
- Bliss J. Chang, MD Cardiology · Albany, NY
- Andrew N. Abboud Student in an Organized Health Care Education/Training Program · Cleveland, OH
- Alejandro Duran Crane, MD Internal Medicine · Cleveland, OH
- Medhat Farwati, MD Student in an Organized Health Care Education/Training Program · Cleveland, OH
- Devora Lichtman, MD Internal Medicine · Cleveland, OH
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.